Grail Raises $390M In Series D Financing To Advance Blood Cancer Test
Executive Summary
Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.
You may also be interested in...
Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021
Grail hopes to launch its Galleri test in 2021 as a laboratory developed test and submit a PMA to the US FDA in 2023.
Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test
Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.
2020 VC Landscape: Reviewing The First Six Months
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.